Literature DB >> 26792062

The endothelial-to-mesenchymal transition and endothelial cilia in EPC-mediated postischemic kidney protection.

D Patschan1, K Schwarze2, E Henze2, S Patschan2, G A Müller2.   

Abstract

Renal ischemia induces peritubular capillary rarefication and fibrosis, with the latter partly resulting from the endothelial-to-mesenchymal transition (EndoMT). Endothelial cilia transmit blood flow-associated forces into the cell. Early endothelial progenitor cells (eEPCs) have been shown to protect mice from acute kidney injury in the short term. The aim of the present study was to analyze midterm consequences of eEPC treatment in the context of endothelial cilia and the EndoMT. Male C57/Bl6N mice were subjected to unilateral renal ischemia postuninephrectomy. Syngeneic murine eEPCs were systemically injected at the time of reperfusion. Animals were investigated 1, 4, and 6 wk later. Cultured mature endothelial cells were exposed to a variable flow with versus without eEPC supernatant incubation. Systemically injected eEPCs reduced serum creatinine levels at week 1 (35 and 45 min) and week 4 (45 min). Interstitial fibrosis was significantly diminished by cell treatment at all time points as well. The EndoMT was less pronounced at week 4 (35 min) and week 6 (45 min). eEPC supernatant reduced α-smooth muscle actin expression and α-tubulin abundance in flow-treated cultured mature endothelial cells, and percentages of cilium-positive cells increased. The loss of peritubular capillaries was prevented by eEPCs. Intrarenal endothelial α-tubulin decreased postischemia and was further reduced by eEPC administration. We conclude that eEPCs are capable of reorganizing the endothelial cytoskeleton in an indirect manner, ultimately resulting in stabilization of the endothelial ciliome. The investigation indicates an antimesenchymal role of endothelial cilia in the process of postischemic tissue fibrosis/EndoMT.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  acute kidney injury; endothelial cilia; endothelial progenitor cells; endothelial-to-mesenchymal transition

Mesh:

Year:  2016        PMID: 26792062     DOI: 10.1152/ajprenal.00306.2015

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  6 in total

Review 1.  Endothelial colony-forming cells and pro-angiogenic cells: clarifying definitions and their potential role in mitigating acute kidney injury.

Authors:  D P Basile; J A Collett; M C Yoder
Journal:  Acta Physiol (Oxf)       Date:  2017-07-25       Impact factor: 6.311

2.  PAC-Mediated AKI Protection Is Critically Mediated but Does Not Exclusively Depend on Cell-Derived Microvesicles.

Authors:  H Dihazi; K Schwarze; S Patschan; G A Müller; O Ritter; M Zeisberg; D Patschan
Journal:  Int J Nephrol       Date:  2021-03-09

3.  Endothelial Colony Forming Cells (ECFCs) in murine AKI - implications for future cell-based therapies.

Authors:  D Patschan; K Schwarze; B Tampe; M Zeisberg; S Patschan; G A Müller
Journal:  BMC Nephrol       Date:  2017-02-06       Impact factor: 2.388

4.  Acute Kidney Injury-Associated Systemic Inflammation Is Aggravated in Insulin-Dependent Diabetes Mellitus.

Authors:  Daniel Patschan; Katrin Schwarze; Elvira Henze; Johanna Charlotte Hoffmann; Susann Patschan; Oliver Ritter; Gerhard Anton Muller
Journal:  J Clin Med Res       Date:  2019-10-04

5.  Constitutive Atg5 overexpression in mouse bone marrow endothelial progenitor cells improves experimental acute kidney injury.

Authors:  Daniel Patschan; Katrin Schwarze; Björn Tampe; Jan Ulrich Becker; Samy Hakroush; Oliver Ritter; Susann Patschan; Gerhard Anton Müller
Journal:  BMC Nephrol       Date:  2020-11-23       Impact factor: 2.388

6.  Human Endothelial Progenitor Cells Protect the Kidney against Ischemia-Reperfusion Injury via the NLRP3 Inflammasome in Mice.

Authors:  Ha Nee Jang; Jin Hyun Kim; Myeong Hee Jung; Taekil Tak; Jung Hwa Jung; Seunghye Lee; Sehyun Jung; Se-Ho Chang; Hyun-Jung Kim
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.